Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages

  Li, Shih Hon ^a   Reinke, Ashley A ^a   Sanders, Karen L ^b   Emal, Cory D ^b   Whisstock, James C ^c   Stuckey, Jeanne A ^d   Lawrence, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b EASTERN MICHIGAN UNIVERSITY   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer; Fibrinolysis; Fibrosis; Thrombolysis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ALLOSTERISM; ARTICLE; BINDING SITE; CELL ADHESION; CELL MIGRATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; HYDROGEN BOND; IC 50; MUTAGENESIS; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; THERMOSTABILITY; X RAY CRYSTALLOGRAPHY;

EID: 84890850269     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216499110     Document Type: Article

References (56)

1. Hamsten A, Wiman B, de Faire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313(25):1557-1563.
2. McMahon GA, et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276(36):33964-33968.
3. Stefansson S, Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin á V â 3 binding to vitronectin. Nature 383(6599):441-443.
4. Huang Y, et al. (2003) A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112 (3):379-388.
5. Eitzman DT, et al. (1996) Bleomycin-Induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97(1):232-237.
6. Pinsky DJ, et al. (1998) Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102(5):919-928.
7. Bjorquist P, et al. (1998) Identification of the binding site for a low-Molecular-Weight inhibitor of plasminogen activator inhibitor type 1 by site-Directed mutagenesis. Biochemistry 37(5):1227-1234.
8. Neve J, et al. (1999) Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod 62(2):324-326.
9. Egelund R, et al. (2001) A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-Neutralizing ligands. Ligand-Induced serpin polymerization. J Biol Chem 276(16):13077-13086.
10. Crandall DL, et al. (2004) Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-Vivo efficacy. J Thromb Haemost 2(8):1422-1428.
11. Gorlatova NV, et al. (2007) Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282(12):9288-9296.
12. Liang A, et al. (2005) Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 115(4):341-350.
13. Gardell SJ, et al. (2007) Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action. Mol Pharmacol 72 (4):897-906.
14. Rupin A, et al. (2008) S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res 122(2):265-270.
15. Izuhara Y, et al. (2008) Inhibition of plasminogen activator inhibitor-1: Its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 28(4): 672-677.
16. Einholm AP, et al. (2003) Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J 373(Pt 3):723-732.
17. Yepes M, Loskutoff DJ, Lawrence DA (2006) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, eds Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ (Lippincott Williams & Wilkins, Baltimore), pp 365-380.
18. Lawrence DA, et al. (2000) Partitioning of serpin-Proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-Sheet A. J Biol Chem 275(8):5839-5844.
19. Lawrence DA, et al. (1995) Serpin-Protease complexes are trapped as stable acyl-Enzyme intermediates. J Biol Chem 270(43):25309-25312.
20. Stratikos E, Gettins PG (1999) Formation of the covalent serpin-Proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-Sheet A. Proc Natl Acad Sci USA 96(9):4808-4813.
21. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-Protease complex shows inhibition by deformation. Nature 407(6806):923-926.
22. Dementiev A, Dobó J, Gettins PG (2006) Active site distortion is sufficient for proteinase inhibition by serpins: Structure of the covalent complex of alpha1-Proteinase inhibitor with porcine pancreatic elastase. J Biol Chem 281(6):3452-3457.
23. Smith KF, Harrison RA, Perkins SJ (1990) Structural comparisons of the native and reactive-Centre-Cleaved forms of alpha 1-Antitrypsin by neutron-And X-Ray-Scattering in solution. Biochem J 267(1):203-212.
24. Mottonen J, et al. (1992) Structural basis of latency in plasminogen activator inhibitor-Nature 355(6357):270-273.
25. Lawrence DA, et al. (1997) Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 272(12):7676-7680.
26. Hekman CM, Loskutoff DJ (1985) Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260(21): 11581-11587.
27. Andreasen PA, Egelund R, Jensen S, Rodenburg KW (1999) Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb Haemost 81(3): 407-414.
28. Gils A, Declerck PJ (1998) Modulation of plasminogen activator inhibitor 1 by Triton X-100 - identification of two consecutive conformational transitions. Thromb Haemost 80(2):286-291.
29. Gorlatova NV, Elokdah H, Fan K, Crandall DL, Lawrence DA (2003) Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 278(18):16329-16335.
30. Dupont DM, et al. (2006) Evidence for a pre-Latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-Strand 1C. J Biol Chem281(47):36071-36081.
31. Mathiasen L, et al. (2008) A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol 74(3):641-653.
32. Li SH, Lawrence DA (2011) Development of inhibitors of plasminogen activator inhibitor-Methods Enzymol 501:177-207.
33. Cale JM, et al. (2010) Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 285(11):7892-7902.
34. Johnson DJ, Li W, Adams TE, Huntington JA (2006) Antithrombin-S195A factor Xaheparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J 25(9):2029-2037.
35. Stefansson S, et al. (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276(11):8135-8141.
36. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-Mediated cell adhesion and release J Cell Biol 134(6):1563-1571.
37. Mayer EJ, Fujita T, Gardell SJ, Shebuski RJ, Reilly CF (1990) The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. Blood 76(8):1514-1520.
38. Seiffert D, Loskutoff DJ (1991) Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 266(5):2824-2830.
39. Xu Z, et al. (2004) Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 279(17):17914-17920.
40. Carrell RW, Owen MC (1985) Plakalbumin, alpha 1-Antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 317(6039):730-732.
41. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D (1994) Engineering plasminogen activator inhibitor-1 (PAI-1) mutants with increased functional stability. Biochemistry 33(12):3643-3648.
42. Komissarov AA, Declerck PJ, Shore JD (2004) Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-Type plasminogen activator. J Biol Chem 279(22): 23007-23013.
43. Xue Y, et al. (1998) Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-Centre loop peptide. Structure 6(5):627-636.
44. Verhamme I, et al. (1999) Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 274(25):17511-17517.
45. Lindahl TL, Sigurdardóttir O, Wiman B (1989) Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62(2):748-751.
46. Berkenpas MB, Lawrence DA, Ginsburg D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14(13):2969-2977.
47. Sharp AM, et al. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7(2):111-118.
48. Gils A, Declerck PJ (1997) Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitorr J Biol Chem 272(19):12662-12666.
49. Gooptu B, et al. (2000) Inactive conformation of the serpin alpha(1)-Antichymotrypsin indicates two-Stage insertion of the reactive loop: Implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 97(1):67-72.
50. Skinner R, et al. (1998) Implications for function and therapy of a 2.9 A structure of binary-Complexed antithrombin. J Mol Biol 283(1):9-14.
51. Li SH, Gorlatova NV, Lawrence DA, Schwartz BS (2008) Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 283(26):18147-18157.
52. Fa M, et al. (1995) Time-Resolved polarized fluorescence spectroscapy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interations with target protease, vitronectin and heparin. Biochem 34 (42):13833-13840.
53. Irving JA, Pike RN, Lesk AM, Whisstock JC (2000) Phylogeny of the serpin superfamily: Implications of patterns of amino acid conservation for structure and function. Genome Res 10(12):1845-1864.
54. Debrock S, Declerck PJ (1997) Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms. Biochim Biophys Acta 1337(2):257-266.
55. Debrock S, Declerck PJ (1998) Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop. Thromb Haemost 79(3): 597-601.
56. Lerner MG, Carlson HA (2006). APBS plug-In for PyMOL. University of Michigan, Ann Arbor.